Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
9 Meters Biopharma, Inc.
This study is an extension of Study CLIN1001-006 (NCT 00492960). This is a Phase IIb, randomized, double-blind, placebo-controlled, dose ranging, multicenter study to determine the safety, tolerance, and efficacy of larazotide acetate in subjects with celiac disease during a gluten challenge. Subjects will remain on their gluten-free diet throughout the duration of the trial.
Study drug or drug placebo capsules will be administered TID 15 minutes before each meal. Gluten or gluten placebo capsules will be taken TID with each meal.
Age
18–72
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female adults with biopsy proven celiac disease on a gluten-free diet for at least the past 6 months
Anti-Tissue Transglutaminase (anti-tTG) ≤ 10 EU.
BMI between 18.5 and 38, inclusive.
You may not be if
Has chronic active GI disease other than celiac disease
Has diabetes (Type 1 or Type 2).
Unable to abstain from alcohol consumption or NSAID use for 48 hours prior to each intestinal permeability collection throughout the study.